Eczema drug study for Kids' growth pulled before starting
NCT ID NCT07187089
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 27 times
Summary
This study was designed to see if the eczema drug dupilumab could help children aged 6 to 12 with severe eczema grow taller and have stronger bones. The drug is already approved for eczema in this age group. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ATOPIC DERMATITIS (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.